WO2023183848A3 - Anti-sars-cov-2 antibodies and methods of use thereof - Google Patents
Anti-sars-cov-2 antibodies and methods of use thereof Download PDFInfo
- Publication number
- WO2023183848A3 WO2023183848A3 PCT/US2023/064817 US2023064817W WO2023183848A3 WO 2023183848 A3 WO2023183848 A3 WO 2023183848A3 US 2023064817 W US2023064817 W US 2023064817W WO 2023183848 A3 WO2023183848 A3 WO 2023183848A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cov
- vaccine
- sars
- cov2
- mrna
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 4
- 229940024452 Janssen COVID-19 vaccine Drugs 0.000 abstract 2
- 241000315672 SARS coronavirus Species 0.000 abstract 2
- 241000701161 unidentified adenovirus Species 0.000 abstract 2
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 abstract 1
- 241000494545 Cordyline virus 2 Species 0.000 abstract 1
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 abstract 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract 1
- 238000013475 authorization Methods 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000517 death Toxicity 0.000 abstract 1
- 229940038694 mRNA-based vaccine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
This disclosure provides novel neutralizing and potent anti-SARS-CoV-2 antibodies, related nucleic acids, related cells, related kits, related compositions, and related methods or uses. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) produced a worldwide pandemic, infecting over 456 million people and responsible for over 6 million deaths. In the United States, the FDA authorized the use of three vaccines encoding prefusion-stabilized SARS15 CoV-2 spike: BNT162b2 from Pfizer-BioNtech, mRNA 1273 from Moderna, and an adenovirus based vaccine, Ad26.COV2.S from Janssen (1). While both mRNA-based vaccines were initially approved as two-dose primary vaccine regimens, the replication-incompetent adenovirus (Ad) 26 vector-based Ad26.COV2.S vaccine received FDA emergency authorization as a single-shot vaccine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323712P | 2022-03-25 | 2022-03-25 | |
| US63/323,712 | 2022-03-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023183848A2 WO2023183848A2 (en) | 2023-09-28 |
| WO2023183848A3 true WO2023183848A3 (en) | 2023-11-30 |
Family
ID=88102191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/064817 WO2023183848A2 (en) | 2022-03-25 | 2023-03-22 | Anti-sars-cov-2 antibodies and methods of use thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023183848A2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021183359A1 (en) * | 2020-03-09 | 2021-09-16 | Abcellera Biologics Inc. | Anti-coronavirus antibodies and methods of use |
| WO2021211332A2 (en) * | 2020-04-13 | 2021-10-21 | Abbott Laboratories | Methods and kits for detecting or determining an amount of an anti-β-coronavirus antibody in a sample |
-
2023
- 2023-03-22 WO PCT/US2023/064817 patent/WO2023183848A2/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021183359A1 (en) * | 2020-03-09 | 2021-09-16 | Abcellera Biologics Inc. | Anti-coronavirus antibodies and methods of use |
| WO2021211332A2 (en) * | 2020-04-13 | 2021-10-21 | Abbott Laboratories | Methods and kits for detecting or determining an amount of an anti-β-coronavirus antibody in a sample |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023183848A2 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021191630A8 (en) | Coronavirus vaccine | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| EP4233898A3 (en) | Influenza mrna vaccines | |
| EP4147708A4 (en) | Traditional chinese medicine composition for treating novel coronavirus pneumonia, preparation method, detection method, and use thereof | |
| EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| Jia et al. | Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection | |
| EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
| WO2022221440A8 (en) | Influenza-coronavirus combination vaccines | |
| ATE415155T1 (en) | ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM, OR TRIAZOLAM BY INHALATION | |
| WO2005120565A8 (en) | Sars vaccines and methods to produce highly potent antibodies | |
| WO2010037027A3 (en) | Immunization of avians by mucosal administration of non-replicating vectored vaccines | |
| WO2009117134A3 (en) | Aerosolized genetic vaccines and methods of use | |
| NO20092254L (en) | Powder formulations for valganciclovir | |
| WO2008096831A1 (en) | Therapeutic agent for cancer | |
| WO2021243122A8 (en) | Engineered coronavirus spike (s) protein and methods of use thereof | |
| MX2021013427A (en) | Methods for treating or preventing asthma by administering an il-33 antagonist. | |
| IL257208A (en) | Modified yeast-brachyury immunotherapeutic compositions | |
| MX2021010545A (en) | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction. | |
| MX2022014161A (en) | Sars-cov-2 vaccines. | |
| WO2005016132A3 (en) | Diagnostics for sars virus | |
| MX2020007777A (en) | Influenza virus vaccines and uses thereof. | |
| MX2022009943A (en) | Intranasal mrna vaccines. | |
| MX2022010877A (en) | Bacterial strains and compositions thereof for oral use in the treatment of viral infections of the respiratory system. | |
| MX2022011504A (en) | Modified mrnas for vaccine development. | |
| WO2023183848A3 (en) | Anti-sars-cov-2 antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23775876 Country of ref document: EP Kind code of ref document: A2 |